Johnson & Johnson Ltd.

CARLSBAD, Calif.--( BUSINESS WIRE )--Arima Genomics, Inc., a company leveraging 3D genomics to reveal actionable insights that will empower researchers and clinicians seeking to improve human health, today announced the appointment of diagnostics industry veterans John Palma, PhD, and Don Hardison to its Board of Directors. In addition to Dr. Palma and Mr. Hardison, the Arima Genomics Board of Directors consists of Elizabeth Brady, Siddarth Selvaraj, and Xin Huang. “3D genomics is proving to be an increasingly important tool for discerning clinically actionable information for improving human health and disease, especially in cancer,” said Siddarth Selvaraj, PhD., Chief Executive Officer at Arima Genomics. “John and Don bring a wealth of operational expertise in cancer diagnostics. With their guidance, we can fully realize the promise of matching every patient to the right targeted therapy.” John Palma is Vice President of Global Medical Affairs at Agilent Technologies, Inc. and brings over 29 years of experience in developing, managing, and delivering complex diagnostics and research products. Over his career, he has consulted with global clinical colleagues and key opinion leaders on advancing high medical value companion diagnostics across the pathology and molecular laboratory customer segments. In addition, John brings deep experience in clinical studies, health outcomes research, product development, and management, having held leadership roles at Agilent, Roche, and Veridex (as a Johnson & Johnson company). “Despite remarkable advancements in cancer diagnostics and therapies over the past decade, diagnostic tools need further discovery and development to yield actionable answers for many patients,” said John Palma. “Arima Genomics has identified an exciting new way to unlock new diagnostic possibilities which could benefit patients with cancer and a range of conditions in the coming years.” Don Hardison has extensive industry leadership experience in executive positions as President and Chief Executive Officer of Biotheranostics, Inc. (now a Hologic company), Good Start Genetics, Inc., and Exact Sciences Corporation, as well as a wide range of experience in the clinical diagnostics field with LabCorp, Quest Diagnostics, and SmithKline Corporation (now GSK). In addition to Arima Genomics, he sits on the boards of BioPorto, Cytek Biosciences, HTG Molecular, and MDXHealth. “There is a revolution in diagnostics whereby a range of new technologies is radically transforming old ways of doing things. Old players are being displaced by emerging companies like Arima Genomics, with novel approaches to answering previously unanswerable questions,” said Don Hardison. “There remains a tremendous opportunity to leverage Arima Genomics’ 3D genomics-based solutions towards new research, translational, and clinical applications.” About Arima Genomics Arima Genomics, Inc. is advancing human health and the life sciences by revealing comprehensive genomic insights. Researchers and clinicians use Arima Genomics’ innovative products and services to gain unparalleled access to the three-dimensional (3D) organization of the genome. This advanced technology enables improvements in human health through identification of biomarkers, an expanded understanding of disease mechanisms, development of novel therapeutic approaches, and solutions for patient management. To learn more, visit www.arimagenomics.com and connect with us on Twitter , LinkedIn , and YouTube .

The technological advancements observed in the biopharmaceutical sector and the rising geriatric population numbers around the world are vital factors that will have a positive impact on the growth of the transdermal drugs market during the assessment period of 2021-2031. The prevalence of chronic diseases is increasing at a rapid rate across various regions. This aspect will also fuel the growth of the transdermal drugs market to a substantial extent. An increase in the adoption of third-generation transdermal drugs will also bring immense growth prospects. Technological advancements and research activities contribute immensely to the growth of the transdermal drugs market. The players indulge in intense research activities. They invest extensively in these activities for finding new formulations and discovering novel insights. All these factors help in increasing the revenues of the players in the transdermal drugs market, eventually increasing the growth rate of the transdermal drugs market. Strategic collaborations have a major part in the growth of the transdermal drugs market. The players frequently indulge in joint ventures, partnerships, and mergers and acquisitions. The collaborations strengthen the position of the players in the transdermal drugs market and also help in carrying out the expansion activities, ultimately contributing in spinning a strong web of growth. Request Brochure of Report - Transdermal Drugs Market: Introduction Transdermal drugs provide improved penetration and control over toxicity levels; patches can be easily removed in case of high toxicity. Drug permeation can be monitored and estimated more effectively, thereby making it highly efficient in maintaining a constant drug level. The three primary routes of drug penetration are appendageal, transcellular, and intercellular. Major constituents of transdermal drug delivery system are pressure sensitive adhesives, drug, enhancers, polymer matrix, membrane, laminate and others Major advantages of transdermal drug delivery are extended therapeutic effect, decrease in drug side-effects, improved bioavailability, better patient compliance, and easy termination of drug therapy Request for Analysis of COVID-19 Impact on Transdermal Drugs Market – Key Drivers, Restrains, and Opportunities of Global Transdermal Drugs Market The global transdermal drugs market is projected to be driven by an increase in patient population, technological developments in the biopharmaceutical industry, and a rise in the demand for non-invasive drug delivery systems Additionally, a surge in strategic collaborations between public and private organizations to promote research & development for improved bioavailability of drugs, increase in the geriatric population, rise in self-administration of drugs at home settings, and a surge in mergers & acquisitions are expected to propel the market during the forecast period However, stringent regulatory guidelines, less awareness in developing countries, and limited availability in smaller economies are expected to restrain the global market Pre book Transdermal Drugs Market Report at North America to Capture Major Share of Global Transdermal Drugs Market North America is expected to account for a major share of the global transdermal drugs market due to the presence of major biopharmaceutical companies, high awareness about non-invasive drug delivery, large patient pool, and increase in the number of product launches in the region Asia Pacific is anticipated to present lucrative opportunities for manufacturers in the transdermal drugs market owing to a rise in the demand for less invasive drug delivery modules, increase in incidence of chronic diseases, rapid increase in geriatric population, expansion of healthcare infrastructure in developing countries such as India, and technological advancements The transdermal drugs market in Latin America and Middle East & Africa is expected to be driven by an increase in adoption of business expansion strategies by major players to strengthen geographic presence and introduction of favorable regulations by governments to promote research & development in these regions For More Information: Top of Form FFF Key Players Operating in Global Transdermal Drugs Market Increase in focus of manufacturers on emerging markets, rise in product approvals, and expansion of product portfolio are anticipated to drive the global transdermal drugs market during the forecast period. Major players operating in the global transdermal drugs market are listed below: Actavis, Inc. Actelion Pharmaceuticals Ltd. 3M BioGel Technology, Inc. Johnson & Johnson Limited Mylan Pharmaceuticals, Inc. Noven Pharmaceuticals, Inc. Novartis AG Janssen Pharmaceuticals, Inc. GlaxoSmithKline plc Boehringer Ingelheim GmbH Upsher-Smith Laboratories, Inc Browse More Trending Reports by Transparency Market Research: Endodontic Files Market: The endodontic files market is estimated to witness promising growth across the forecast period of 2019-2027. The escalating demand for dental care coupled with a rise in government initiatives will serve as vital growth factors for the endodontic files market. The increasing need to reduce procedural errors is prompting the players in the endodontic files market to develop advanced This aspect will add extra stars of growth to the endodontic files market. Dental Mallets Market: The appearance of cutting-edge dentistry, electro-attractive and attractive mallets that give added highlights, and more capable working have hit the business sectors is likely to bode well for the growth of the global market for dental mallets. These attractive mallets are proposed to improve the specialist's effectiveness in doing explicit medical procedures and implantology. A dental hammer gives the specialist an assortment of choices for cutting-edge bone expansion strategies. Attractive and electro-attractive mallets dispense with the weaknesses and restrictions of manual mallets and offer dental specialists a higher authority over the pressing factor, weight, and speed during the use of a mallet. About Us Transparency Market Research is a next-generation market intelligence provider, offering fact-based solutions to business leaders, consultants, and strategy professionals. Our reports are single-point solutions for businesses to grow, evolve, and mature. Our real-time data collection methods along with ability to track more than one million high growth niche products are aligned with your aims. The detailed and proprietary statistical models used by our analysts offer insights for making right decision in the shortest span of time. For organizations that require specific but comprehensive information we offer customized solutions through ad hoc reports. These requests are delivered with the perfect combination of right sense of fact-oriented problem solving methodologies and leveraging existing data repositories. TMR believes that unison of solutions for clients-specific problems with right methodology of research is the key to help enterprises reach right decision. Contact Mr. Rohit Bhisey Transparency Market Research State Tower, 90 State Street, Suite 700, Albany NY - 12207 United States USA - Canada Toll Free: 866-552-3453 Email: sales@transparencymarketresearch.com Website:

HUNTINGDON VALLEY, Pa., Oct. 24 /PRNewswire-FirstCall/ -- Byron D. Hewett, President and CEO, and other members of senior management will provide an Immunicon update and discuss third quarter earnings results via Webcast and conference call on Wednesday November 1, 2006, at 9:00 a.m. EST. What: Immunicon Corporation's Third Quarter 2006 Financial Earnings Call and Webcast When: Wednesday, November 1, 2006 at 9:00 a.m. EST How: To participate in the live call by telephone, the dial-in number for domestic U.S. listeners is (866) 713-8395 using passcode: 83450282. International callers may dial (617) 597-5309 using passcode: 83450282. In addition, a live audio webcast of the call will be available online at Immunicon's corporate Web site at . Webcast participants are encouraged to log on to the site at least 15 minutes prior to the scheduled start time to register, download, and install any necessary audio software. Contact: Denise Portner, Tierney Communications, (215) 790-4395 Following the call, a webcast audio replay will be available on the Company's web site for 30 days through Friday, November 29, 2006. In addition, a dial-in replay will be maintained for 5 days through Monday, November 6, and can be accessed by dialing (888) 286-8010 (U.S. listeners) or (617) 801-6888 (International dialers) using reservation code: 37463886. The conference call audio will also be distributed over the Thomson/CCBN Investor Distribution Network to both institutional and individual investors. Individual investors can listen to the call through the Thomson/CCBN individual investor center at or by visiting any of the investor sites in the Thomson/CCBN Individual Investor Network. Institutional investors can access the call via the Thomson/CCBN password-protected event management site, StreetEvents ( ). About Immunicon Corporation Immunicon Corporation is developing and commercializing proprietary cell- and molecular-based human diagnostic and life science research products, and is providing certain analytical services to pharmaceutical and biotechnology companies to assist them in developing new therapeutic agents, with an initial focus on cancer disease management. Immunicon has developed platform technologies to identify, count and characterize a small number of rare cells in blood, such as circulating tumor cells and circulating endothelial cells that are important in many diseases and biological processes. Immunicon's products and underlying technology platforms also have application in cancer research and may have applications in other fields of medicine, such as cardiovascular and infectious diseases. For more information, please visit . Forward-Looking Statements This press release may contain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are often preceded by words such as "hope," "may," "believe," "anticipate," "plan," "expect," "intend," "assume," "will" and similar expressions. Forward-looking statements contained in this press release include, among others, statements relating to the anticipated clinical utility of Immunicon's products and other statements not of historical fact. Immunicon cautions investors not to place undue reliance on these forward- looking statements, which speak only as of the date of this press release, are based on the current expectations and intent of the management of Immunicon and involve certain factors, such as risks and uncertainties that may cause actual results to be far different from those suggested by these statements. These statements are not guarantees of future performance and involve risks and uncertainties that are difficult to predict, including, but not limited to, risks and uncertainties associated with: Immunicon's dependence on Veridex, LLC, a Johnson & Johnson company, in the field of cancer cell analysis; the ability to earn license and milestone payments under Immunicon's agreement with Veridex; Immunicon's capital and financing needs; research and development and clinical trial expenditures; commercialization of product candidates; Immunicon's ability to obtain licenses from third parties to commercialize products; Immunicon's ability to manage its growth; obtaining necessary regulatory approvals; reliance on third party manufacturers and suppliers; reimbursement by third party payors to Immunicon's customers; compliance with applicable manufacturing standards; retaining key personnel; delays in the development of new products or planned improvements to products; effectiveness of products compared to competitors' products; protection of Immunicon's intellectual property; conflicts with third party intellectual property; product liability lawsuits that may be brought against Immunicon; labor, contract or technical difficulties; and competitive pressures in Immunicon's industry. These factors are discussed in more detail in Immunicon's filings with the Securities and Exchange Commission. Except as required by law, Immunicon accepts no responsibility for updating the information contained in this press release beyond the published date, whether as a result of new information, future events or otherwise, or for modifications made to this document by Internet or wire services. "Immunicon" and the Immunicon Corporation logo are registered trademarks of Immunicon Corporation. ALL RIGHTS RESERVED. Contact Information: James G. Murphy SVP of Finance & Administration, CFO 215-346-8313 jmurphy@immunicon.com Investors/Media: Tierney Communications Denise Portner Vice President 215-790-4395 dportner@tierneyagency.com Immunicon Corporation CONTACT: James G. Murphy, SVP of Finance & Administration, CFO ofImmunicon Corporation, +1-215-346-8313 or jmurphy@immunicon.com, orInvestors/Media: Denise Portner, Vice President of Tierney Communicationsfor Immunicon Corporation, +1-215-790-4395 or dportner@tierneyagency.com Web site: